GlassScriptPhysician profile
Mary J Britton
NPI 1053318246
$8,880.75
in general payments reported to CMS, 2019-2025
46 companies · $1,495 in 2025
The $1,495 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,512 · 2020: $890 · 2021: $897 · 2022: $1,328 · 2023: $1,510 · 2024: $1,249 · 2025: $1,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,203 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,203.36 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,318.25 | 2021-2025 | |
| Abbvie INC. | $1,186.31 | 2021-2025 | Ubrelvy, Linzess, Viberzi |
| Sanofi-Aventis U.S. LLC | $1,075.55 | 2019-2023 | |
| Glaxosmithkline, LLC. | $569.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $533.77 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $429.15 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $408.53 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $399.56 | 2019-2025 | |
| Amgen INC. | $393.89 | 2019-2025 | Evenity, Repatha, Prolia |
| Dexcom, INC. | $282.51 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $269.45 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.00 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $177.36 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $135.00 | 2022-2023 | |
| Abbott Laboratories | $133.84 | 2019-2025 | Freestyle Insulinx, Freestyle Libre 3 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Britton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.